ROZLYTREK | Disease support

Request medical information

Prescribing information

What is ROZLYTREK?

Introduction to ROZLYTREK
MoA and CNS activity

ROS1+ NSCLC

Study design
Patient characteristics
Efficacy
CNS efficacy

NTRK fusion+ solid tumours

Study design
Patient characteristics
Efficacy
CNS efficacy

ROZLYTREK safety overview

ROZLYTREK safety summary
ROZLYTREK adverse reactions
Monitoring

Prescribing ROZLYTREK

ROZLYTREK dosing
Download the ROZLYTREK SmPC

Patient benefits

Lung cancer patient
Breast cancer patient
Sarcoma patient

Gene fusion detection

Introduction to clinically actionable fusions
NTRK
ROS1
Testing guidelines

Disease support

Coming soon

Request medical information

Prescribing information

Bring the potential of ROZLYTREK^® to life

Disease support

Disease support

Coming soon

© 2021. RF. Hoffmann-La Roche Ltd.

About Roche
Contact us
Legal statement
Privacy
Cookie Preferences
Your local portal

M-XX-00003955 Date of preparation: July 2021

This site is intended for those outside the United States.

Contact the Roche Precision Medicine Partner in your area

How would you like to be contacted?

We aim to get in touch within one business day

Disclaimer: I consent to my data being processed for the purpose of responding to my inquiry and in accordance with the Roche Global Privacy Policy & Privacy Notice for Pharmacovigilance